Idenix Announces Data Presentation at the 48th Annual Meeting of the European
Association for the Study of the Liver (EASL)
CAMBRIDGE, Mass., April 8, 2013 (GLOBE NEWSWIRE) -- Idenix Pharmaceuticals,
Inc. (Nasdaq:IDIX), a biopharmaceutical company engaged in the discovery and
development of drugs for the treatment of human viral diseases, today
announced that it will present data on IDX719, the Company's pan-genotypic HCV
NS5A inhibitor, at the 48^th Annual Meeting of the European Association for
the Study of the Liver (EASL) which is being held April 24 – 28, 2013 in
Amsterdam, the Netherlands. Full abstracts can now be viewed at the EASL
website at www.easl.eu.
McCarville, et al, "Treatment-Emergent Variants Following 3 Days of
Monotherapy with IDX719, a Potent, Pan-Genotypic NS5A Inhibitor, in Subjects
Infected with HCV Genotypes 1-4", will be presented in a poster session on
Saturday, April 27.
Idenix Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts, is a
biopharmaceutical company engaged in the discovery and development of drugs
for the treatment of human viral diseases. Idenix's current focus is on the
treatment of infections caused by hepatitis C virus. For further information
about Idenix, please refer to www.idenix.com.
This press release contains "forward-looking statements" for purposes of the
safe harbor provisions of The Private Securities Litigation Reform Act of
1995. For this purpose, any statements contained herein that are not
statements of historical fact may be deemed forward-looking statements.
Without limiting the foregoing, the words "expect," "plans," "anticipates,"
"intends," "will," and similar expressions are also intended to identify
forward-looking statements, as are any expressed or implied statements with
respect to: the Company's plans to continue to developing nucleotide
polymerase inhibitors for HCV; its clinical development plans for its uridine
nucleotide analog drug candidate and IDX719; its plans to advance other
preclinical nucleotides; and statements regarding the efficacy and safety of
its clinical compounds. Actual results may differ materially from those
indicated by such forward-looking statements as a result of risks and
uncertainties, including but not limited to the following: there can be no
guarantees that the Company will advance any clinical product candidate or
other component of its potential pipeline to the clinic, to the regulatory
process or to commercialization due to numerous risks inherent in
pharmaceutical research and development; management's expectations could be
affected by unexpected regulatory actions or delays; uncertainties relating
to, or unsuccessful results of, preclinical and clinical trials, including
additional data relating to the ongoing clinical trials evaluating its product
candidates; the Company's ability to obtain additional funding required to
conduct its research, development and commercialization activities;
competition; and the Company's ability to obtain, maintain and enforce patent
and other intellectual property protection for its product candidates and its
discoveries. Such forward-looking statements involve known and unknown risks,
uncertainties and other important factors that may cause actual results to be
materially different from any future results, performance or achievements
expressed or implied by such statements. These and other risks which may
impact management's expectations are described in greater detail under the
heading "Risk Factors" in the Company's annual report on Form 10-K for the
year ended December 31, 2012, as filed with the Securities and Exchange
Commission (SEC) and in any subsequent periodic or current report that the
Company files with the SEC.
All forward-looking statements reflect the Company's estimates only as of the
date of this release (unless another date is indicated) and should not be
relied upon as reflecting the Company's views, expectations or beliefs at any
date subsequent to the date of this release. While Idenix may elect to update
these forward-looking statements at some point in the future, it specifically
disclaims any obligation to do so, even if the Company's estimates change.
CONTACT: Idenix Pharmaceuticals Contacts:
Kelly Barry (617) 995-9033 (media)
Teri Dahlman (617) 995-9807 (investors)
Press spacebar to pause and continue. Press esc to stop.